NCT04691180View on ClinicalTrials.gov

A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 5, 2021

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions
COVID-19
Interventions
DRUG

BRII-196 and BRII-198

BRII-196 and BRII-198 given intravenously

DRUG

Placebo

Placebo given intravenously

Trial Locations (1)

100015

Investigative Site, Beijing

Sponsors
All Listed Sponsors
collaborator

TSB Therapeutics (Beijing) CO.LTD

INDUSTRY

lead

Brii Biosciences Limited

INDUSTRY